The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA to Review Immediate-Release Oxycodone; Plus NICE Recommends Secukinumab

FDA to Review Immediate-Release Oxycodone; Plus NICE Recommends Secukinumab

May 1, 2017 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Oxycodone Tablets Submitted to FDA
Filings for oxycodone tablets (Oxaydo) in both 10 and 15 mg doses have been accepted by the U.S. Food and Drug Administration (FDA).1 The submission is based on a pharmacokinetic study demonstrating bioequivalence to the reference drug, oxycodone hydrochloride (Roxicodone) tablets at a 15 mg dose. The product is an immediate-release formulation of oxycodone for treating acute and chronic moderate to severe pain for which the use of an opioid is appropriate.

You Might Also Like
  • FDA Responds to New Drug Application for Baricitinib
  • FDA to Review Abuse Deterrent Oxycodone Capsule & More
  • Abaloparatide Promising for Osteoporosis; NICE Draft Guidelines Include Secukinumab for Ankylosing Spondylitis
Also By This Author
  • Rituximab for RA Is Safe Long Term, Plus Oxycodone Update

Initially approved in December 2015 in both 5 and 7.5 mg doses, the treatment is designed to discourage intranasal abuse. It contains an inactive ingredient that may cause nasal burning if the formulation is manipulated and snorted. However, this formulation has not been proved to reduce abuse compared with immediate-release oxycodone.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The FDA is expected to review these formulations for potential approval by mid-June 2017.

NICE Recommends Secukinumab Use for Psoriatic Arthritis
Secukinumab (Cosentyx) is an interleukin (IL) 17A inhibitor clinically shown to significantly improve skin and joint symptoms in patients with psoriatic arthritis, while improving patients’ physical function and quality of life. In the U.K., the National Institute for Health and Care Excellence (NICE) has published a positive Final Appraisal Determination, recommending to the National Health Service (NHS) the use of secukinumab in adults with active and progressive psoriatic arthritis.2 The treatment is also recommended for use by patients with peripheral arthritis who have three or more tender and swollen joints without having a prior response to at least two standard disease-modifying anti-rheumatic drugs (DMARDs), either as mono- or combination therapy. Secukinumab can also be used in patients who are unresponsive to a TNF-alpha inhibitor within the first 12 weeks, or when TNF-alpha inhibitors are contraindicated. The NICE recommendation acknowledges the clinical importance of secukinumab as a new standard for treating psoriatic arthritis patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In July 2015, NICE approved secukinumab for restricted use within the NHS, in Wales and England, to treat adults with moderate to severe plaque psoriasis. In August 2016, the NHS approved secukinumab to treat adults with ankylosing spondylitis when non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors were not suitable or were ineffective.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Egalet Corp. News release: Egalet announces U.S. Food and Drug Administration acceptance of file for prior approval supplement for Oxaydo (oxycodone HCl, USP) tablets C-II 10 mg and 15 mg dosage strengths. 2017 April 18.
  2. McKee S. NICE nod for Novartis’ Cosentyx in PsA. PharmTimes Online. 2017 Apr 19.

Pages: 1 2 | Single Page

Filed Under: Analgesics, Biologics & Biosimilars, Drug Updates Tagged With: FDA, Food and Drug Administration, Opioids, Psoriatic Arthritis, secukinumab

You Might Also Like:
  • FDA Responds to New Drug Application for Baricitinib
  • FDA to Review Abuse Deterrent Oxycodone Capsule & More
  • Abaloparatide Promising for Osteoporosis; NICE Draft Guidelines Include Secukinumab for Ankylosing Spondylitis
  • Scottish Medicines Consortium Recommends Risankizumab; Plus Real-World Data on Secukinumab

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)